- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Blue Jet Healthcare's FY26 was foundational, with ₹947 Cr revenue (down 8% YoY) amid mixed operating segments. Q4 saw strong Contrast Media growth (₹193 Cr, up 91% YoY). PI/API faced destocking, but the "worst is behind," with expectations to exceed FY25 peaks. The company is investing ₹1,000 Cr in its Vizag greenfield and ₹40 Cr in a Hyderabad R&D center, focusing on new chemistry platforms like peptides and GLP-1. New product launches across segments and lateral entries are planned. Management is confident in these capacity and pipeline investments to drive future growth. The company remains debt-free with ₹400 Cr in liquid assets.